Figure 4.

Interleukin 1β/tumor necrosis factor α-induced loss of glycosaminoglycans and collagen II was blocked by cotreatment with PKF115-584. (A) Metatarsals were treated with interleukin 1β (IL-1β) and tumor necrosis factor α (TNFα) (10 ng/ml each) in combination with small molecule WNT/β-catenin inhibitors (1.0 µM). PKF115-584 preserved morphology and glycosaminoglycan staining. A representative picture of two independent experiments is shown. Scale bar represents 500 µm. Boxed areas represent areas represented in B. (B) Magnification of the boxed region in (A). Scale bar represents 100 µm. (C) After 7 days of treatment, PKF115-584 (1.0 µM) prevented IL-1β and TNFα (10 ng/ml each)-induced loss of collagen II staining. A representative picture of three independent experiments is shown. Scale bar represents 100 µm.

Landman et al. Arthritis Research & Therapy 2013 15:R93   doi:10.1186/ar4273
Download authors' original image